X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    mAbs And Therapeutic Proteins Potency Guidance Issued By FDA

    Novel Purification Means For Protein Drug Manufacturing

    $118bn Sales By 2026 Is What Japanese Pharma Can Expect

    $118bn Sales By 2026 Is What Japanese Pharma Can Expect

    Duchenne Muscular Dystrophy-Cancer Genetic Link Discovered

    Animal Testing Could See An End With An Artificial Model

    Bioavailability Enhancement Market Projects CAGR of 11%

    Hong Kong Gives $500mn Funding For Chinese Drug Development

    Germany Rolls First CAR-T Push For Muscle Inflammation Cure

    More Monitoring Required of Institutional Review Boards

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    mAbs And Therapeutic Proteins Potency Guidance Issued By FDA

    Novel Purification Means For Protein Drug Manufacturing

    $118bn Sales By 2026 Is What Japanese Pharma Can Expect

    $118bn Sales By 2026 Is What Japanese Pharma Can Expect

    Duchenne Muscular Dystrophy-Cancer Genetic Link Discovered

    Animal Testing Could See An End With An Artificial Model

    Bioavailability Enhancement Market Projects CAGR of 11%

    Hong Kong Gives $500mn Funding For Chinese Drug Development

    Germany Rolls First CAR-T Push For Muscle Inflammation Cure

    More Monitoring Required of Institutional Review Boards

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Pharma Responds To The Statutory Scheme Surge By The UK

Content Team by Content Team
9th March 2023
in News

The UK government has gone on to confirm its plans to move ahead with the proposed statutory scheme pharma rate surge. This means that the revenue recovery rate paid by the pharma companies that are subject to the statutory scheme for branded medicines will increase to 27.5% from the present 24.4%.

The Association of the British Pharmaceutical Industry- ABPI as well as one of the major global pharma companies have responded to this move, pointing out that the plans don’t happen to be supportive when it comes to the life sciences sector. The statutory scheme happens to be one of the two that keeps check on the branded medicine prices for the NHS. It is well to note that any organisation that gives out licensed branded medicines to the NHS is subject to the statutory scheme option unless it selects to join Medicines Pricing and Access. Through this scheme, the government looks to make sure that all the medicines supplied are at an affordable price, both in the broader economy as well as in the life sciences sector.

As per the ABPI, the finding suggests that sustaining such high costs for another half a decade will cause a loss of £50 billion to the UK’s GDP by 2058. Retaining high rates till 2033 would entail foregoing yet another £90 billion in GDP and a total of £29.9 billion when it comes to associated tax revenues until 2058.

The chief executive of ABPI, Richard Torbett, said that it is indeed very disappointing that the payment rate increase has been put in place. He also went on to warn that, based on the latest research that was recently published, such rates go on to impact the investment decisions of any company and also have quite a damaging impact.

The government has stated that such changes are expected to result in savings to the tune of £17 million to £19 million for the NHS by 2023. That said, Laura Steele, who happens to be the president and general manager of a global pharmaceutical giant, opined that the decision to increase the already sky-high recovery rate diminishes UK’s plans of becoming a science superpower and the government’s push towards fostering an environment for innovation in the life sciences.

Steele went on to conclude that they remain committed to collaborating with the UK government, the NHS, as well as the broader sector so as to look for a solution. She added that with so much to gain for UK patients, they by all means must look into repairing the present medicine pricing grid.

Previous Post

Novel Purification Means For Protein Drug Manufacturing

Next Post

mAbs And Therapeutic Proteins Potency Guidance Issued By FDA

Related Posts

Drug Development

mAbs And Therapeutic Proteins Potency Guidance Issued By FDA

9th March 2023
Drug Development

Novel Purification Means For Protein Drug Manufacturing

9th March 2023
$118bn Sales By 2026 Is What Japanese Pharma Can Expect
Drug Development

$118bn Sales By 2026 Is What Japanese Pharma Can Expect

2nd March 2023
Drug Development

Duchenne Muscular Dystrophy-Cancer Genetic Link Discovered

28th February 2023
News

Animal Testing Could See An End With An Artificial Model

28th February 2023
News

Bioavailability Enhancement Market Projects CAGR of 11%

28th February 2023
Next Post

mAbs And Therapeutic Proteins Potency Guidance Issued By FDA

Latest News

Drug Development

mAbs And Therapeutic Proteins Potency Guidance Issued By FDA

9th March 2023
News

Pharma Responds To The Statutory Scheme Surge By The UK

9th March 2023
Drug Development

Novel Purification Means For Protein Drug Manufacturing

9th March 2023
Pharmapack 2023 a pivotal moment for sustainability in drug delivery and packaging
Europe

Pharmapack 2023 a pivotal moment for sustainability in drug delivery and packaging

3rd March 2023
$118bn Sales By 2026 Is What Japanese Pharma Can Expect
Drug Development

$118bn Sales By 2026 Is What Japanese Pharma Can Expect

2nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In